Intercept Pharmaceuticals, Inc. — Cyborg Score 6/10
Solid
Specialty pharmaceuticals for rare liver diseases
Strategic Profile
Intercept delivered strong double-digit growth of Ocaliva as of Q2 2023, with the company positioned as a leader in rare and serious liver disease therapeutics. The development pipeline includes INT-767, a dual FXR/TGR5 agonist, and INT-777, a TGR5 agonist. Following its acquisition by Alfasigma, the company's assets are now integrated into a larger European pharmaceutical conglomerate with expanded gastrointestinal and hepatology capabilities.
Cyborg Score Rationale
As an acquired private subsidiary, Intercept maintains a commercial product generating meaningful revenue in a focused rare disease market. However, limited public disclosure post-acquisition and prior regulatory setbacks (FDA rejection of NASH indication in 2020) temper growth trajectory. The company benefits from Alfasigma's broader platform and resources but operates in a niche hepatology segment with modest total addressable market.
Top Insights
Ocaliva net sales reached $83.7 million in Q2 2023, representing 17% growth over the prior year quarter
The FDA rejected obeticholic acid (OCA) for NASH in June 2020, determining that predicted benefit did not sufficiently outweigh predicted risks
The company updated 2023 full-year Ocaliva net sales guidance to $320–$340 million
Intercept now operates as a private subsidiary of Alfasigma, limiting independent strategic flexibility but providing access to parent company resources and international distribution
Named Competitors
Gilead Sciences Hepatology Portfolio — FXR agonists and hepatology therapeutics
VK2735 — Dual GLP-1/GCG agonist for metabolic diseases including NASH
Resmetirom — First-in-class non-steroidal FXR agonist for NASH
Recent Developments
(November 2023) Alfasigma completed acquisition of Intercept Pharmaceuticals for $19.00 per share
(Q2 2023) Ocaliva delivered 17% year-over-year net sales growth to $83.7 million
(2023) Company updated full-year Ocaliva net sales guidance to $320–$340 million
Open the full interactive Intercept Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.